We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 3.64% | 228.00 | 227.50 | 229.50 | 228.00 | 221.00 | 222.00 | 75,464 | 12:22:42 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.80 | 216.82M |
From Apr 2019 to Apr 2024
TIDMOXB
RNS Number : 3490L
Oxford Biomedica PLC
18 July 2017
Director Dealings / Market Share Sale and Purchase
Oxford, UK - 18 July 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 14 July 2017 James Miskin, Chief Technical Officer, exercised 930,000 options at 1p and sold all of the resulting shares at 8.1p. Following this transaction he holds 7,104,836 options and no shares in the company.
The issued share capital of the Company is 3,094,999,848 1p ordinary shares.
-Ends-
For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 John Dawson, Chief Executive 783 000 Officer Tim Watts, Chief Financial Officer Financial and corporate communications Tel: +44 (0)20 3709 enquiries: 5700 Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCRPMRTMBIBMJR
(END) Dow Jones Newswires
July 18, 2017 03:47 ET (07:47 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
